GlassScriptPhysician profile
John Scott Adams
NPI 1093004061
$8,524.11
in general payments reported to CMS, 2019-2025
40 companies · $914 in 2025
The $914 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,330 · 2020: $1,729 · 2021: $1,125 · 2022: $612 · 2023: $923 · 2024: $891 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677 · Education: $51.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.50 |
| Education | $51.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,205.29 | 2019-2024 | Senza |
| Collegium Pharmaceutical, INC. | $874.86 | 2019-2025 | Xtampza |
| Stimwave Technologies Incorporated | $629.76 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $458.68 | 2019-2025 | Relistor |
| Globus Medical, INC. | $439.06 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $437.49 | 2019-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $362.67 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $301.92 | 2019-2022 | |
| Pfizer INC. | $281.39 | 2019-2024 | |
| Abbott Laboratories | $230.83 | 2020-2024 | Proclaim |
| Amgen INC. | $204.73 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $187.56 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $177.56 | 2019 | |
| Medtronic USA, INC. | $152.41 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $142.71 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.56 | 2021-2024 | Qulipta |
| Curonix LLC | $124.27 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $114.45 | 2020-2025 | Sprint Pns System |
| Allergan, INC. | $98.83 | 2019-2021 | |
| Boston Scientific Corporation | $84.42 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $83.39 | 2019-2021 | |
| Electronic Waveform Lab, INC. | $73.03 | 2019 | |
| Spinal Simplicity, LLC | $71.28 | 2024-2025 | Ha Minuteman G3-R |
| Assertio Therapeutics, INC. | $67.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.85 | 2019 | |
| Kaleo, INC. | $56.46 | 2019 | |
| Nalu Medical, INC. | $54.83 | 2021-2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $50.80 | 2024-2025 | Qutenza |
| Azurity Pharmaceuticals, INC. | $50.62 | 2023-2024 | Horizant, Edarbi, Horizant |
| Mdd US Operations, LLC | $50.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.23 | 2019 | |
| Zyla Life Sciences, INC. | $39.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.30 | 2022 | |
| Medtronic, INC. | $32.44 | 2021-2025 | Inceptiv |
| Astrazeneca Pharmaceuticals LP | $19.56 | 2019 | |
| Si-Bone, INC. | $17.54 | 2024 | |
| Flowonix Medical Incorporated | $17.09 | 2019 | |
| Saluda Medical Americas, INC. | $15.70 | 2024 | Evoke |
| Protega Pharmaceutials INC | $15.12 | 2025 | Roxybond |
| Lilly USA, LLC | $13.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.